AIM ImmunoTech Shareholders Elect All Three Company Director Nominees at 2022 Annual Meeting
November 03 2022 - 12:34PM
Business Wire
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the
“Company”) today announced that shareholders have re-elected all
three of the Company’s directors, Stewart L. Appelrouth, Thomas K.
Equels and William M. Mitchell, at the Company’s Annual Meeting of
Shareholders (the “Annual Meeting”) held today.
AIM issued the following statement:
“We are grateful to our shareholders for their support and
engagement. Going forward, we will continue our work to expand on
our already significant progress in repurposing our lead drug,
Ampligen, into oncology, and positioning the Company to deliver
long-term value to shareholders.”
The results announced today have been tabulated and certified by
the independent Inspector of Elections. The Company will file the
final voting results on a Form 8-K with the Securities and Exchange
Commission.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the
research and development of therapeutics to treat multiple types of
cancers, immune disorders, and viral diseases, including COVID-19.
The Company’s lead product, Ampligen® (rintatolimod) is an
immuno-modulator with broad spectrum activity being developed for
globally important cancers, viral diseases and disorders of the
immune system.
Ampligen is currently being used as a monotherapy to treat
pancreatic cancer patients in an Early Access Program (EAP)
approved by the Inspectorate of Healthcare in the Netherlands at
Erasmus Medical Center and AIM has commenced a Phase 2 clinical
study in 2022. The Company also has multiple ongoing clinical
trials to evaluate Ampligen as a combinational therapy for the
treatment of a variety of solid tumor types both underway and
planned at major cancer research centers. Additionally, Ampligen is
approved in Argentina for the treatment of severe chronic fatigue
syndrome (CFS) and is currently being evaluated in many aspects of
SARS-CoV-2/COVID-19 myalgic encephalomyelitis/chronic fatigue
syndrome (ME/CFS) and Post COVID Conditions.
For more information, please visit aimimmuno.com and connect
with the Company on Twitter, LinkedIn, and Facebook.
Forward-Looking
Statements
This press release contains certain forward-looking statements
that involve risks, uncertainties and assumptions that are
difficult to predict. Words and expressions reflecting optimism,
satisfaction or disappointment with current prospects, as well as
words such as “believes,” “hopes,” “intends,” “estimates,”
“expects,” “projects,” “plans,” “anticipates” and variations
thereof, or the use of future tense, identify forward-looking
statements, but their absence does not mean that a statement is not
forward-looking. The Company’s forward-looking statements are not
guarantees of performance, and actual results could vary materially
from those contained in or expressed by such statements due to
risks, uncertainties and other factors. The Company urges investors
to consider specifically the various risk factors identified in its
most recent Form 10-K, and any risk factors or cautionary
statements included in any subsequent Form 10-Q or Form 8-K, filed
with the Securities and Exchange Commission. You are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. Except as required
by law, the Company does not undertake any responsibility to update
any forward-looking statements to take into account events or
circumstances that occur after the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221103005865/en/
Investor:
JTC Team, LLC Jenene Thomas 833-475-8247 AIM@jtcir.com
OR
Morrow Sodali AIM@investor.MorrowSodali.com
Media:
Longacre Square Partners Joe Germani / Dan Zacchei
jgermani@longacresquare.com / dzacchei@longacresquare.com
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Mar 2024 to Apr 2024
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Apr 2023 to Apr 2024